Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: A proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy

Radiology

Volumn 260, Issue 2, 2011, Pages 581-590

  Williams, Ross ^a   Hudson, John M ^a,c   Lloyd, Brendan A ^a   Sureshkumar, Ahthavan R ^a,c   Lueck, Gordon ^a   Milot, Laurent ^b   Atri, Mostafa ^d   Bjarnason, Georg A ^e   Burns, Peter N ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PERFLUTREN; SUNITINIB;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VOLUME; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED ULTRASONOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; MALE; MICROBUBBLE; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; CARCINOMA, RENAL CELL; CONTRAST MEDIA; EVIDENCE-BASED MEDICINE; FEMALE; FLUOROCARBONS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICROBUBBLES; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960686957     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11101893     Document Type: Article

References (28)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-3590.
3. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759. (Pubitemid 46797957)
4. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010;9(1):15-19.
5. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26(28):4572-4578.
6. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194(1):157-165.
7. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006;42(15):2472-2479. (Pubitemid 44442955)
8. Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010;16(4):1216-1225.
9. Guibal A, Taillade L, Mulé S, et al. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology 2010;254(2):420-429.
10. Pollard RE, Broumas AR, Wisner ER, Vekich SV, Ferrara KW. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 2007;33(2):235-245. (Pubitemid 46240595)
11. Niermann KJ, Fleischer AC, Huamani J, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007;26(6):749-756. (Pubitemid 46870342)
12. De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005;11(17):6171- 6176. (Pubitemid 41262944)
13. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006;187(5):1267-1273. (Pubitemid 44630831)
14. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008;43(2):100-111.
15. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97(5):473-483. (Pubitemid 28090220)
16. Arditi M, Frinking PJ, Zhou X, Rognin NG. A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2006;53(6):1118-1129. (Pubitemid 46405092)
17. Hudson JM, Karshafian R, Burns PN. Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. Ultrasound Med Biol, 2009;35(12):2007-2020.
18. Rognin N, Frinking P, Costa M, Arditi M. In-vivo perfusion quantification by contrast ultrasound: validation of the use of linearized video data vs. raw RF data. In: Proceedings of the IEEE Ultrasonics Symposium. Piscataway, NJ: Institute of Electrical and Electronics Engineers, 2008 ;1690-1693.
19. Bogaard JM, Smith SJ, Versprille A, Wise ME, Hagemeijer F. Physiological interpretation of the skewness of indicator-dilution curves: theoretical considerations and a practical application. Basic Res Cardiol 1984;79(4):479-493. (Pubitemid 14053186)
20. Mischi M, den Boer JA, Korsten HH. On the physical and stochastic representation of an indicator dilution curve as a gamma variate. Physiol Meas 2008;29(3):281-294. (Pubitemid 351423040)
21. Thévenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process 1998;7(1):27-41. (Pubitemid 128745320)
22. Lueck G, Hudson JM, Williams R, Sureshkumar A, Martel A, Burns PN. Combined image registration methods for parametric contrast imaging of tumour blood flow. In: 14th European Symposium on Ultrasound Contrast Imaging, 22-23 January 2009, Rotterdam, the Netherlands. Rotterdam, the Netherlands: International Contrast Ultrasound Society, 2009 ;67-69. ICUS Web site. http://www.echocontrast.nl/. Accessed April 13, 2011.
23. Wang FM, Karshafian R, Burns PN. A real-time clinical ultrasound contrast dosimeter with adaptive algorithms. In: Proceedings of the IEEE Ultrasonics Symposium. Piscataway, NJ: Institute of Electrical and Electronics Engineers, 2004;2057-2060.
24. Becher H, Burns PN. A handbook of contrast echocardiography: left ventricular function and myocardial perfusion. Berlin, Germany: Springer, 2000.
25. Averkiou M, Lampaskis M, Kyriakopoulou K, et al. Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy. Ultrasound Med Biol 2010;36(1):68-77.
26. Renault G, Tranquart F, Perlbarg V, Bleuzen A, Herment A, Frouin F. A posteriori respiratory gating in contrast ultrasound for assessment of hepatic perfusion. Phys Med Biol 2005;50(19):4465-4480. (Pubitemid 41361511)
27. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21(1):21-26.
28. Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification - preliminary results. Radiology 2011;258(1):291-300.